A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
TerminatedPhase 2NCT00625833
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a trial to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving chronic peripheral pain suffered by patients with diabetes. Some evidence for the effectiveness of \[S,S\]- Reboxetine in relieving chronic pain has been seen in 3 completed trials.
Study details
- Official title
- A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
- Conditions
- Interventions
- Drug: Placebo
- Drug: [S,S]-Reboxetine
- Sponsor
- Pfizer
- Start date
- 2007-12
- Primary completion
- 2008-11
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Czechia, Finland, Netherlands, South Africa, Spain, United States
- Total sites listed
- 56
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female of any race at least 18 years of age * Diagnosis of painful, distal, symmetrical, sensory-motor polyneuropathy, which is due to diabetes, for at least 1 year * Patients at Visit 1 must have a score ≥40 mm on the Pain Visual Analogue Scale Exclusion Criteria: * Patients with significant hepatic impairment * Neurological disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathic pain * Any pain or other condition that may confound assessment or self-evaluation of the pain due to diabetic neuropathy * Amputations other than toes * A current or recent diagnosis (past 6 months) or episode of major depressive disorder and/or uncontrolled depression * History of transient ischemic attack or stroke * Myocardial infarction or unstable angina within the past three months
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00625833